Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate

By João L. Carapinha

December 17, 2024

NICE (National Institute for Health and Clinical Excellence) recently commented on whether their cost-effectiveness thresholds should change, focusing on the intricate relationship between quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER). The ongoing debate about NICE’s cost-effectiveness thresholds reveals important concerns and insights relevant to healthcare technology assessment.

Ongoing Debate on QALYs

The use of QALYs in cost-effectiveness analysis remains a contentious issue. Critics argue that QALYs may not adequately capture the complexity of health outcomes and can be discriminatory, especially against specific patient groups. In NICE’s context, the debate centers on whether QALYs should be adjusted to reflect continuous economic growth and willingness to pay for innovation. Despite these discussions, QALYs continue to be a prevalent metric in the UK for evaluating health interventions.

Cost-Effectiveness Thresholds

Historically, NICE has employed a cost-effectiveness threshold range of £20,000 to £30,000 per QALY gained. This threshold is essential for determining whether new healthcare technologies offer good value for money. However, the NICE blog post argues that merely increasing the cost per QALY may not remedy access issues to innovative healthcare technologies. Rather, we highlight the need for the ICER to accurately reflect the country’s growing economic development and societal willingness to pay for innovation.

Economic Development and Willingness to Pay

The UK’s cost-effectiveness threshold has remained relatively static, which may signal a lag in the country’s willingness to invest in innovative healthcare technologies, compared to its international peers. It is crucial for these thresholds to adapt alongside economic shifts and changing societal values to maintain their relevance and effectiveness.

Positive Recommendations and Fixed Thresholds

Despite the ongoing debates, NICE has recommended positive outcomes for 86% of applications, demonstrating a generally supportive stance towards new technologies. The cost-effectiveness threshold is set to remain unchanged until 2028, which offers a degree of stability for healthcare providers and manufacturers.

Methodological Elements and Future Contributions

The continuous methodological discussions are significant, particularly regarding the adjustments of thresholds. Contributing to this discussion can enhance the process of determining appropriate cost-effectiveness thresholds. Factors such as uncertainty in the evidence base, disease burden, and alternative treatment availability all play vital roles in informing NICE’s decisions.

In summary, NICE explores the complex and multifaceted discussions surrounding cost-effectiveness thresholds and QALYs. We highlight the need for thresholds to be dynamic and reflective of broader economic and societal changes while also focussing on the importance of methodological rigor in these evaluations. The examination of NICE’s cost-effectiveness thresholds provides essential insights for further engagement in this crucial debate.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.